Welcome to our dedicated page for DAXOR news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on DAXOR stock.
Daxor Corporation reports developments tied to blood volume measurement technology, including commercialization of its FDA-cleared Blood Volume Analysis diagnostics and the BVA-100 Blood Volume Analyzer. Company news commonly covers clinical data, cardiology and critical-care use cases, new customer programs, conference presentations, and product updates for rapid, portable BVA systems.
Daxor also issues updates on financial results, shareholder communications, capital actions, and market expansion for its ezBVA Lab workflow and related diagnostic services. Its coverage centers on precision fluid management, heart failure, ICU care, and adoption of direct blood, plasma, and red-cell volume measurement in clinical settings.
Daxor Corporation (Nasdaq: DXR) reported a 49.4% increase in year-over-year sales of its single-use diagnostic kits. The company also achieved a 10.4% growth in sales from Q1 to Q2 2022, benefitting from new accounts and increased capital equipment purchases. Recent successes include a major acquisition at a leading Illinois academic center and expansion within a major South Carolina healthcare organization servicing 1.5 million patients. Ongoing clinical studies and contracts with the U.S. military are not included in these figures but are contributing additional revenue.
Daxor (Nasdaq: DXR) has partnered with MedAxiom to enhance the adoption of its blood volume analysis (BVA) technology. This collaboration aims to improve patient outcomes, reduce healthcare costs, and optimize clinician experiences as heart failure diagnoses rise. Daxor's BVA technology has demonstrated significant improvements in patient metrics, including an 82% decrease in 30-day mortality and enhanced treatment plans with 98% accuracy. The partnership leverages MedAxiom's extensive network to accelerate technology delivery in the cardiovascular community, aligning with healthcare’s Quadruple Aim.
Daxor Corporation (Nasdaq: DXR) has secured funding from the National Institute of Health (NIH) to enhance its clinical decision support software aimed at improving heart failure treatment.
The company participated in the NIH's Innovation Corps (I-Corps™) program, which supports businesses ready for commercialization of NIH-funded projects. This program provided vital resources to accelerate the launch of Daxor’s software, designed to optimize fluid management in acute heart failure.
Daxor Corporation (Nasdaq: DXR) has entered a Cooperative Research and Development Agreement with The Uniformed Services University and The Henry M. Jackson Foundation. The collaboration aims to develop a non-nuclear blood volume diagnostic device, enhancing the existing BVA-100 technology. This device is designed for both military and civilian use, targeting conditions like trauma and heart failure. Extensive studies validate Daxor's technology, showing a potential for improved patient outcomes by significantly enhancing fluid management in critical care.
Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, will exhibit at the American Association of Heart Failure Nurses 18th Annual Meeting from June 15-18, 2022, in Orlando, Florida. They aim to educate healthcare professionals on their blood volume technology, which reportedly reduces 30-day mortality by 82% and readmissions by 56%. Daxor has conducted over 60,000 tests across the U.S., contributing to better patient outcomes in various medical conditions, including heart failure.
Daxor Corporation (Nasdaq: DXR) announced its participation in a National Institutes of Health (NIH) study on neurologic function after COVID-19 infection, utilizing its BVA-100 technology. Led by Dr. Avindra Nath at the NIH's National Institute of Neurological Disorders and Stroke, the study aims to address lingering symptoms from COVID-19, such as 'brain fog.' CEO Michael Feldschuh highlighted the clinical utility of the BVA-100, which is commonly used in hospitals. Daxor is also developing a next-generation portable analyzer under contract with the Department of Defense.
Daxor Corporation (Nasdaq: DXR) will present at the H.C. Wainwright Global Life Investment Hybrid Conference from May 23-26, 2022, in Miami Beach, FL. CEO Michael Feldschuh will speak on May 25 at 4:30 PM ET, highlighting the company's achievements in financial performance, product commercialization, and collaborations with the U.S. Department of Defense and the National Institute of Health. Daxor's BVA-100® blood test is pivotal in managing critical care, COVID-19, and heart failure, with over 60,000 tests conducted. Interested parties can register for the event and request one-on-one meetings.
Daxor Corporation (Nasdaq: DXR) has presented new data at the ISHLT Annual Meeting showcasing the efficacy of its BVA-100 blood test in enhancing survival rates for advanced heart failure patients using LVADs. The study revealed that 91% of patients with LVADs exhibited abnormal blood volume, indicating the test's critical role in patient management. With a 98% accuracy rate, the BVA-100 test helps identify derangements in blood volume, potentially improving patient outcomes. Daxor emphasizes its commitment to advancing healthcare through blood volume analysis technology.
Daxor Corporation (Nasdaq: DXR) presented new data from a study at the 71st American College of Cardiology meeting on April 2, revealing the effectiveness of the BVA-100 test in measuring intravascular congestion in heart failure patients. This test outperformed common clinical tools, which were found ineffective. The study led by Dr. Vishal N. Rao emphasized that blood volume measurements do not correlate with cardiac pressures, indicating the superiority of Daxor's approach in improving patient outcomes in heart failure management.
Daxor Corporation (Nasdaq: DXR) announced that CEO Michael Feldschuh will present at the Maxim Group 2022 Virtual Growth Conference from March 28-30, 2022. The presentation will cover recent achievements, including contracts with the U.S. Department of Defense, NIH grant funding, and clinical trials for its BVA-100® blood test aimed at critical care management, COVID-19, and heart failure. Registration is required to attend the conference and view the presentation.